Bioatla to participate in the citizens life sciences conference

San diego, april 30, 2025 (globe newswire) -- bioatla, inc. (nasdaq: bcab), a global clinical-stage biotechnology company focused on the development of conditionally active biologic (cab) antibody therapeutics for the treatment of solid tumors, today announced that the company's management will provide a corporate update and participate in one-on-one investor meetings at the citizens life sciences conference, to be held in new york, ny may 7-8, 2025.
BCAB Ratings Summary
BCAB Quant Ranking